Patents by Inventor Bryan Becklund

Bryan Becklund has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multivalent and Multispecific 41BB-Binding Proteins
    Publication number: 20230416387
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: December 16, 2022
    Publication date: December 28, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • SIGLEC-8 BINDING PROTEINS AND USES THEREOF
    Publication number: 20230406925
    Abstract: Provided herein are Siglec-8 binding proteins, and methods of using Siglec-8 binding proteins to modulate the biological activity of Siglec-8.
    Type: Application
    Filed: July 28, 2023
    Publication date: December 21, 2023
    Inventors: Tony Dung-Ling Yao, Andrew M. Eckles, Jacob J. Gano, Bryan Becklund, Brendan P. Eckelman
  • OX40-Binding Polypeptides and Uses Thereof
    Publication number: 20230128188
    Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: August 8, 2022
    Publication date: April 27, 2023
    Applicant: Inhibrx, Inc.
    Inventors: John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
  • PDL1-binding proteins
    Patent number: 11566078
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: January 31, 2023
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • OX40-binding polypeptides and uses thereof
    Patent number: 11447556
    Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: September 20, 2022
    Assignee: Inhibex, Inc.
    Inventors: John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
  • Multivalent and Multispecific OX40-Binding Fusion Proteins
    Publication number: 20220106397
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Application
    Filed: August 10, 2021
    Publication date: April 7, 2022
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multivalent and multispecific OX40-binding fusion proteins
    Patent number: 11117972
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: September 14, 2021
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Hata, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multivalent and Multispecific 41BB-Binding Fusion Proteins
    Publication number: 20200199243
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: October 15, 2019
    Publication date: June 25, 2020
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • OX40-BINDING POLYPEPTIDES AND USES THEREOF
    Publication number: 20200055946
    Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: August 12, 2019
    Publication date: February 20, 2020
    Applicant: Inhibrx, Inc.
    Inventors: John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
  • Multivalent and multispecific 41BB-binding fusion proteins
    Patent number: 10501551
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: December 10, 2019
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Hata, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multivalent and Multispecific OX40-Binding Fusion Proteins
    Publication number: 20190263916
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Application
    Filed: March 7, 2019
    Publication date: August 29, 2019
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Hata, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rason, Quinn Deveraux
  • MULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS
    Publication number: 20170198050
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: January 11, 2017
    Publication date: July 13, 2017
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Hata, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rason, Quinn Deveraux
  • MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS
    Publication number: 20170198051
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Application
    Filed: January 11, 2017
    Publication date: July 13, 2017
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Hata, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rason, Quinn Deveraux
  • Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
    Publication number: 20070105774
    Abstract: Methods for treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally, 1,25-dihydroxyvitamin D analogs can be used in combination with the calcitonin, calcitonin-like peptides or calcitonin mimetics.
    Type: Application
    Filed: October 19, 2006
    Publication date: May 10, 2007
    Inventors: Hector DeLuca, Terrence Meehan, Bryan Becklund, Margaret Clagett-Dame
  • Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
    Publication number: 20060189532
    Abstract: Methods for treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally, 1,25-dihydroxyvitamin D analogs can be used in combination with the calcitonin, calcitonin-like peptides or calcitonin mimetics.
    Type: Application
    Filed: February 13, 2006
    Publication date: August 24, 2006
    Inventors: Hector DeLuca, Terrence Meehan, Bryan Becklund, Margaret Clagett-Dame